Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis

Sodani, Pietro; Mucci, Luciano; Girolimetti, Rita; Tedesco, Silvia; Monaco, Francesco; Campanozzi, Daniele; Brunori, Marino; Maltoni, S.; Bedetta, Samuele; Carlo, Anna Maria Di; Candoli, Piero; Mancini, Mauro; Rebonato, Alberto; D'Adamo, F; Capalbo, Maria; Frausini, G

doi:10.1016/j.rmcr.2020.101115

Cited by 17 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because, it was reported that 30% of COVID-19 patients in the ICU experienced bronchoalveolar lavage (BAL) and worsening hypoxia so that the bronchoscopy procedure could be used to prevent multidrug resistance antibiotics [9] , [14] . The efficacy of bronchoscopy in COVID-19 has not been published numerically but bronchoscopy can increase lung capacity in patients over 50 years of age [15] .…”

Section: Discussionmentioning

confidence: 99%

Increase of lung function usage bronchoscopy in COVID-19 patients: Three case series in Indonesian adult

Muljono¹,

Marhana²,

Syafa’ah³

et al. 2021

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Increase of lung function usage bronchoscopy in COVID-19 patients: Three case series in Indonesian adult

Muljono¹,

Marhana²,

Syafa’ah³

et al. 2021

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

“…To date, although the drug has been approved for severe patients by the FDA and EMA, the results cannot be considered uniformly conclusive as some clinical trials have shown discordant results [5][6][7][8][9][10][11]. The first randomized, placebo-controlled, phase III clinical trial with remdesivir was published in 2020.…”

Section: Some Clinically Effective Antivirals Against Covid-19mentioning

confidence: 99%

Pharmacological treatment of COVID-19: an opinion paper

García‐Lledó¹,

Gómez-Pavón²,

Castillo³

et al. 2021

Rev Esp Quimioter

View full text Add to dashboard Cite

The precocity and efficacy of the vaccines developed so far against COVID-19 has been the most significant and saving advance against the pandemic. The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among existing drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation.

show abstract

“…There is also a relation between cytokine elevation and the severity of COVID-19 disease [29]. In a case report study, a 50-year-old man with follicular non-Hodgkin lymphoma successfully recovered from COVID-19 after receiving remdesivir, baricitinib, tocilizumab hydroxychloroquine, and broad-spectrum antibiotics [71]. In another study by Izumo and colleagues on 44 patients with severe COVID-19, it has been shown that combination therapy using baricitinib, remdesivir, and dexamethasone (BRD) was effective, and the incidence rate of AEs was low.…”

Section: Baricitinib Combination Therapies Against Covid-19mentioning

confidence: 99%

Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection

Akbarzadeh-Khiavi

Torabi

Rahbarnia³

et al. 2021

Infection

View full text Add to dashboard Cite

Purpose The Coronavirus disease 2019 (COVID-19) pandemic is one of the most devastating global problems. Regarding the lack of disease-specific treatments, repurposing drug therapy is currently considered a promising therapeutic approach in pandemic situations. Recently, the combination therapy of Janus kinase (JAK) inhibitor baricitinib has been authorized for emergency COVID-19 hospitalized patients; however, this strategy's safety, drug-drug interactions, and cellular signaling pathways remain a tremendous challenge. Methods In this study, we aimed to provide a deep insight into the baricitinib combination therapies in severe COVID-19 patients through reviewing the published literature on PubMed, Scopus, and Google scholar databases. We also focused on cellular and subcellular pathways related to the synergistic effects of baricitinib plus antiviral agents, virus entry, and cytokine storm (CS) induction. The safety and effectiveness of this strategy have also been discussed in moderate to severe forms of COVID-19 infection. Results The severity of COVID-19 is commonly associated with a dysregulated immune response and excessive release of pro-inflammatory agents, resulting in CS. It has been shown that baricitinib combined with antiviral agents could modulate the inflammatory response and provide a series of positive therapeutic outcomes in hospitalized adults and pediatric patients (age ≥ two years old). Conclusion Baricitinib plus the standard of care treatment might be a potential strategy in hospitalized patients with severe COVID-19.

show abstract

Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis

Cited by 17 publications

References 15 publications

Increase of lung function usage bronchoscopy in COVID-19 patients: Three case series in Indonesian adult

Increase of lung function usage bronchoscopy in COVID-19 patients: Three case series in Indonesian adult

Pharmacological treatment of COVID-19: an opinion paper

Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection

Contact Info

Product

Resources

About